Analysts’ Viewpoint on Europe and Middle East & Africa Respiratory Panel Testing Market Scenario
Healthcare brands in the Europe and Middle East & Africa respiratory panel testing market are unlocking value-grab opportunities through eCommerce to keep economies running during the ongoing COVID-19 pandemic. However, several respiratory pathogens can cause nearly indistinguishable symptoms. Hence, manufacturers should develop panels that provide fast and comprehensive results with a run time of less than an hour. Quick turnaround on a broad menu of pathogens may also help clinicians make vital decisions regarding admission, isolation, and additional diagnostic testing. The high prevalence of seasonal influenza, human rhinovirus, and viral infections is fueling the demand for respiratory panel testing. High sensitivity and specificity is preferred in respiratory panels.
Rapid and automated detection of pathogens is significantly changing in the Europe and Middle East & Africa respiratory panel testing market. There is a demand for panels that test multiple viruses and bacteria that cause respiratory tract infections. Manufacturers are increasing the availability of panels that eliminate the need for precise measuring or pipetting. Fast turnaround time is preferred in respiratory panel testing.
High sensitivity and specificity in respiratory panel testing is helping to boost product sales. Panels based on TGA (Therapeutic Goods Administration)-certified multiplex PCR (polymerase chain reaction) systems are boosting the credibility of healthcare brands. FDA-cleared and CE marked panels are helping to improve patient outcomes.
SARS-CoV-2 has become a top concern for patients and healthcare practitioners. Companies in the Europe and Middle East & Africa respiratory panel testing market are increasing the availability of products to reduce the stress of clinicians. However, several respiratory pathogens can cause nearly indistinguishable symptoms. Hence, companies are increasing R&D investment to develop FDA De Novo authorized panels that help clinicians to quickly diagnose respiratory infections, including COVID-19, RSV, influenza, and the likes.
Manufacturers in the Europe and Middle East & Africa respiratory panel testing market are developing products that use a syndromic approach to accurately detect and identify the pathogens most commonly associated with respiratory infections. These panels are being used in combination with rapid respiratory PCR test results to enable better-informed diagnosis and treatment of patients.
PCR-based panels are increasingly replacing viral culture to detect pathogens. However, companies in the Europe and Middle East & Africa respiratory panel testing market should increase the availability of products to support pathogen detection, which is useful for clinicians and clinical microbiologists. PCR-based panels are emerging as an alternative to viral culture, since the latter is slow and labor-intensive. These panels are gaining popularity for the detection of viral nucleic acids and provide prompt results with high sensitivity & specificity.
Manufacturers are boosting the production for multiplex PCR-based respiratory viral panels for the test of influenza, respiratory syncytial virus (RSV), and rhinovirus, among others.
The high prevalence of both self-limiting upper respiratory tract infections (RTIs) and more severe lower RTIs such as bronchitis & pneumonitis is fueling the demand for respiratory panel testing. It has been found that lower RTIs are a major cause for hospitalization, morbidity, and mortality in infants and the elderly. In order to reduce their treatment cost, respiratory panel testing is emerging as an effective strategy.
Companies in the Europe and Middle East & Africa respiratory panel testing market are capitalizing on incremental opportunities, since PCR-based panels are a preferred option for the evaluation of severely immunocompromised patients with respiratory symptoms. The high prevalence of parainfluenza, human metapneumovirus (hMPV), and adenovirus is driving the demand for respiratory panel products.
In order to tap revenue opportunities through eCommerce, manufacturers in the Europe and Middle East & Africa respiratory panel testing market are developing products that help to collect specimens through nasopharyngeal swab. The growing trend of home testing provided by labs is another driver contributing to market growth. The Europe and Middle East & Africa respiratory panel testing market is expanding due to product demand for testing human rhinovirus and human metapneumovirus, among others.
|
Attribute |
Detail |
|
Market Size Value in 2020 |
US$ 1.6 Bn |
|
Market Forecast Value in 2031 |
US$ 3.1 Bn |
|
Growth Rate (CAGR) |
5.1% |
|
Forecast Period |
2021–2031 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes cross segment analysis as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competitive Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Europe and Middle East & Africa Respiratory Panel Testing Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, 2018–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industry Events (Mergers, Acquisitions, Partnerships, etc.)
5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, by Specimen Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
6.3.1. Viruses
6.3.1.1. Adenovirus
6.3.1.2. Severe Acute Respiratory Syndrome
6.3.1.3. RSV
6.3.1.4. Human Metapneumovirus
6.3.1.5. Rhinovirus/Enterovirus
6.3.1.6. Parainfluenza Virus
6.3.1.7. Flu A
6.3.1.8. Others
6.3.2. Bacteria
6.3.2.1. Mycoplasma Pneumoniae
6.3.2.2. Chlamydophila Pneumonia
6.4. Europe and Middle East & Africa Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type
7. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, by Panel Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031
7.3.1. Syndromic Full Multiplex Panel
7.3.2. Low Plex Panel
7.4. Europe and Middle East & Africa Respiratory Panel Testing Market Attractiveness Analysis, by Panel Type
8. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
8.3.1. Hospital Point-of-Care testing
8.3.2. Reference Labs
8.3.3. Hospitals
8.3.4. Others
8.4. Europe and Middle East & Africa Respiratory Panel Testing Market Attractiveness Analysis, by End-user
9. Europe and Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Region
9.2.1. Europe
9.2.2. Middle East & Africa
9.3. Europe and Middle East & Africa Respiratory Panel Testing Market Attractiveness Analysis, by Country/Region
10. Europe Respiratory Panel Testing Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
10.2.1. Viruses
10.2.1.1. Adenovirus
10.2.1.2. Severe Acute Respiratory Syndrome
10.2.1.3. RSV
10.2.1.4. Human Metapneumovirus
10.2.1.5. Rhinovirus/Enterovirus
10.2.1.6. Parainfluenza Virus
10.2.1.7. Flu A
10.2.1.8. Others
10.2.2. Bacteria
10.2.2.1. Mycoplasma Pneumoniae
10.2.2.2. Chlamydophila Pneumonia
10.3. Market Value Forecast, by Panel Type, 2017–2031
10.3.1. Syndromic Full Multiplex Panel
10.3.2. Low Plex Panel
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospital Point-of-Care testing
10.4.2. Ref Laboratories
10.4.3. Hospitals
10.4.4. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. Germany
10.5.1.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.1.1.1. Viruses
10.5.1.1.1.1. Adenovirus
10.5.1.1.1.2. Severe Acute Respiratory Syndrome
10.5.1.1.1.3. RSV
10.5.1.1.1.4. Human Metapneumovirus
10.5.1.1.1.5. Rhinovirus/Enterovirus
10.5.1.1.1.6. Parainfluenza Virus
10.5.1.1.1.7. Flu A
10.5.1.1.1.8. Others
10.5.1.1.2. Bacteria
10.5.1.1.2.1. Mycoplasma Pneumoniae
10.5.1.1.2.2. Chlamydophila Pneumonia
10.5.1.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.1.2.1. Syndromic Full Multiplex Panel
10.5.1.2.2. Low Plex Panel
10.5.1.3. Market Value Forecast, by End-user, 2017–2031
10.5.1.3.1. Hospital Point-of-Care testing
10.5.1.3.2. Ref Laboratories
10.5.1.3.3. Hospitals
10.5.1.3.4. Others
10.5.2. U.K.
10.5.2.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.2.1.1. Viruses
10.5.2.1.1.1. Adenovirus
10.5.2.1.1.2. Severe Acute Respiratory Syndrome
10.5.2.1.1.3. RSV
10.5.2.1.1.4. Human Metapneumovirus
10.5.2.1.1.5. Rhinovirus/Enterovirus
10.5.2.1.1.6. Parainfluenza Virus
10.5.2.1.1.7. Flu A
10.5.2.1.1.8. Others
10.5.2.1.2. Bacteria
10.5.2.1.2.1. Mycoplasma Pneumoniae
10.5.2.1.2.2. Chlamydophila Pneumonia
10.5.2.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.2.2.1. Syndromic Full Multiplex Panel
10.5.2.2.2. Low Plex Panel
10.5.2.3. Market Value Forecast, by End-user, 2017–2031
10.5.2.3.1. Hospital Point-of-Care testing
10.5.2.3.2. Ref Laboratories
10.5.2.3.3. Hospitals
10.5.2.3.4. Others
10.5.3. France
10.5.3.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.3.1.1. Viruses
10.5.3.1.1.1. Adenovirus
10.5.3.1.1.2. Severe Acute Respiratory Syndrome
10.5.3.1.1.3. RSV
10.5.3.1.1.4. Human Metapneumovirus
10.5.3.1.1.5. Rhinovirus/Enterovirus
10.5.3.1.1.6. Parainfluenza Virus
10.5.3.1.1.7. Flu A
10.5.3.1.1.8. Others
10.5.3.1.2. Bacteria
10.5.3.1.2.1. Mycoplasma Pneumoniae
10.5.3.1.2.2. Chlamydophila Pneumonia
10.5.3.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.3.2.1. Syndromic Full Multiplex Panel
10.5.3.2.2. Low Plex Panel
10.5.3.3. Market Value Forecast, by End-user, 2017–2031
10.5.3.3.1. Hospital Point-of-Care testing
10.5.3.3.2. Ref Laboratories
10.5.3.3.3. Hospitals
10.5.3.3.4. Others
10.5.4. Italy
10.5.4.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.4.1.1. Viruses
10.5.4.1.1.1. Adenovirus
10.5.4.1.1.2. Severe Acute Respiratory Syndrome
10.5.4.1.1.3. RSV
10.5.4.1.1.4. Human Metapneumovirus
10.5.4.1.1.5. Rhinovirus/Enterovirus
10.5.4.1.1.6. Parainfluenza Virus
10.5.4.1.1.7. Flu A
10.5.4.1.1.8. Others
10.5.4.1.2. Bacteria
10.5.4.1.2.1. Mycoplasma Pneumoniae
10.5.4.1.2.2. Chlamydophila Pneumonia
10.5.4.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.4.2.1. Syndromic Full Multiplex Panel
10.5.4.2.2. Low Plex Panel
10.5.4.3. Market Value Forecast, by End-user, 2017–2031
10.5.4.3.1. Hospital Point-of-Care testing
10.5.4.3.2. Ref Laboratories
10.5.4.3.3. Hospitals
10.5.4.3.4. Others
10.5.5. Spain
10.5.5.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.5.1.1. Viruses
10.5.5.1.1.1. Adenovirus
10.5.5.1.1.2. Severe Acute Respiratory Syndrome
10.5.5.1.1.3. RSV
10.5.5.1.1.4. Human Metapneumovirus
10.5.5.1.1.5. Rhinovirus/Enterovirus
10.5.5.1.1.6. Parainfluenza Virus
10.5.5.1.1.7. Flu A
10.5.5.1.1.8. Others
10.5.5.1.2. Bacteria
10.5.5.1.2.1. Mycoplasma Pneumoniae
10.5.5.1.2.2. Chlamydophila Pneumonia
10.5.5.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.5.2.1. Syndromic Full Multiplex Panel
10.5.5.2.2. Low Plex Panel
10.5.5.3. Market Value Forecast, by End-user, 2017–2031
10.5.5.3.1. Hospital Point-of-Care testing
10.5.5.3.2. Ref Laboratories
10.5.5.3.3. Hospitals
10.5.5.3.4. Others
10.5.6. Benelux
10.5.6.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.6.1.1. Viruses
10.5.6.1.1.1. Adenovirus
10.5.6.1.1.2. Severe Acute Respiratory Syndrome
10.5.6.1.1.3. RSV
10.5.6.1.1.4. Human Metapneumovirus
10.5.6.1.1.5. Rhinovirus/Enterovirus
10.5.6.1.1.6. Parainfluenza Virus
10.5.6.1.1.7. Flu A
10.5.6.1.1.8. Others
10.5.6.1.2. Bacteria
10.5.6.1.2.1. Mycoplasma Pneumoniae
10.5.6.1.2.2. Chlamydophila Pneumonia
10.5.6.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.6.2.1. Syndromic Full Multiplex Panel
10.5.6.2.2. Low Plex Panel
10.5.6.3. Market Value Forecast, by End-user, 2017–2031
10.5.6.3.1. Hospital Point-of-Care testing
10.5.6.3.2. Ref Laboratories
10.5.6.3.3. Hospitals
10.5.6.3.4. Others
10.5.7. Poland
10.5.7.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.7.1.1. Viruses
10.5.7.1.1.1. Adenovirus
10.5.7.1.1.2. Severe Acute Respiratory Syndrome
10.5.7.1.1.3. RSV
10.5.7.1.1.4. Human Metapneumovirus
10.5.7.1.1.5. Rhinovirus/Enterovirus
10.5.7.1.1.6. Parainfluenza Virus
10.5.7.1.1.7. Flu A
10.5.7.1.1.8. Others
10.5.7.1.2. Bacteria
10.5.7.1.2.1. Mycoplasma Pneumoniae
10.5.7.1.2.2. Chlamydophila Pneumonia
10.5.7.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.7.2.1. Syndromic Full Multiplex Panel
10.5.7.2.2. Low Plex Panel
10.5.7.3. Market Value Forecast, by End-user, 2017–2031
10.5.7.3.1. Hospital Point-of-Care testing
10.5.7.3.2. Ref Laboratories
10.5.7.3.3. Hospitals
10.5.7.3.4. Others
10.5.8. Sweden
10.5.8.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.8.1.1. Viruses
10.5.8.1.1.1. Adenovirus
10.5.8.1.1.2. Severe Acute Respiratory Syndrome
10.5.8.1.1.3. RSV
10.5.8.1.1.4. Human Metapneumovirus
10.5.8.1.1.5. Rhinovirus/Enterovirus
10.5.8.1.1.6. Parainfluenza Virus
10.5.8.1.1.7. Flu A
10.5.8.1.1.8. Others
10.5.8.1.2. Bacteria
10.5.8.1.2.1. Mycoplasma Pneumoniae
10.5.8.1.2.2. Chlamydophila Pneumonia
10.5.8.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.8.2.1. Syndromic Full Multiplex Panel
10.5.8.2.2. Low Plex Panel
10.5.8.3. Market Value Forecast, by End-user, 2017–2031
10.5.8.3.1. Hospital Point-of-Care testing
10.5.8.3.2. Ref Laboratories
10.5.8.3.3. Hospitals
10.5.8.3.4. Others
10.5.9. Denmark
10.5.9.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.9.1.1. Viruses
10.5.9.1.1.1. Adenovirus
10.5.9.1.1.2. Severe Acute Respiratory Syndrome
10.5.9.1.1.3. RSV
10.5.9.1.1.4. Human Metapneumovirus
10.5.9.1.1.5. Rhinovirus/Enterovirus
10.5.9.1.1.6. Parainfluenza Virus
10.5.9.1.1.7. Flu A
10.5.9.1.1.8. Others
10.5.9.1.2. Bacteria
10.5.9.1.2.1. Mycoplasma Pneumoniae
10.5.9.1.2.2. Chlamydophila Pneumonia
10.5.9.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.9.2.1. Syndromic Full Multiplex Panel
10.5.9.2.2. Low Plex Panel
10.5.9.3. Market Value Forecast, by End-user, 2017–2031
10.5.9.3.1. Hospital Point-of-Care testing
10.5.9.3.2. Ref Laboratories
10.5.9.3.3. Hospitals
10.5.9.3.4. Others
10.5.10. Finland
10.5.10.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.10.1.1. Viruses
10.5.10.1.1.1. Adenovirus
10.5.10.1.1.2. Severe Acute Respiratory Syndrome
10.5.10.1.1.3. RSV
10.5.10.1.1.4. Human Metapneumovirus
10.5.10.1.1.5. Rhinovirus/Enterovirus
10.5.10.1.1.6. Parainfluenza Virus
10.5.10.1.1.7. Flu A
10.5.10.1.1.8. Others
10.5.10.1.2. Bacteria
10.5.10.1.2.1. Mycoplasma Pneumoniae
10.5.10.1.2.2. Chlamydophila Pneumonia
10.5.10.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.10.2.1. Syndromic Full Multiplex Panel
10.5.10.2.2. Low Plex Panel
10.5.10.3. Market Value Forecast, by End-user, 2017–2031
10.5.10.3.1. Hospital Point-of-Care testing
10.5.10.3.2. Ref Laboratories
10.5.10.3.3. Hospitals
10.5.10.3.4. Others
10.5.11. Norway
10.5.11.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.11.1.1. Viruses
10.5.11.1.1.1. Adenovirus
10.5.11.1.1.2. Severe Acute Respiratory Syndrome
10.5.11.1.1.3. RSV
10.5.11.1.1.4. Human Metapneumovirus
10.5.11.1.1.5. Rhinovirus/Enterovirus
10.5.11.1.1.6. Parainfluenza Virus
10.5.11.1.1.7. Flu A
10.5.11.1.1.8. Others
10.5.11.1.2. Bacteria
10.5.11.1.2.1. Mycoplasma Pneumoniae
10.5.11.1.2.2. Chlamydophila Pneumonia
10.5.11.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.11.2.1. Syndromic Full Multiplex Panel
10.5.11.2.2. Low Plex Panel
10.5.11.3. Market Value Forecast, by End-user, 2017–2031
10.5.11.3.1. Hospital Point-of-Care testing
10.5.11.3.2. Ref Laboratories
10.5.11.3.3. Hospitals
10.5.11.3.4. Others
10.5.12. Switzerland
10.5.12.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.12.1.1. Viruses
10.5.12.1.1.1. Adenovirus
10.5.12.1.1.2. Severe Acute Respiratory Syndrome
10.5.12.1.1.3. RSV
10.5.12.1.1.4. Human Metapneumovirus
10.5.12.1.1.5. Rhinovirus/Enterovirus
10.5.12.1.1.6. Parainfluenza Virus
10.5.12.1.1.7. Flu A
10.5.12.1.1.8. Others
10.5.12.1.2. Bacteria
10.5.12.1.2.1. Mycoplasma Pneumoniae
10.5.12.1.2.2. Chlamydophila Pneumonia
10.5.12.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.12.2.1. Syndromic Full Multiplex Panel
10.5.12.2.2. Low Plex Panel
10.5.12.3. Market Value Forecast, by End-user, 2017–2031
10.5.12.3.1. Hospital Point-of-Care testing
10.5.12.3.2. Ref Laboratories
10.5.12.3.3. Hospitals
10.5.12.3.4. Others
10.5.13. Austria
10.5.13.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.13.1.1. Viruses
10.5.13.1.1.1. Adenovirus
10.5.13.1.1.2. Severe Acute Respiratory Syndrome
10.5.13.1.1.3. RSV
10.5.13.1.1.4. Human Metapneumovirus
10.5.13.1.1.5. Rhinovirus/Enterovirus
10.5.13.1.1.6. Parainfluenza Virus
10.5.13.1.1.7. Flu A
10.5.13.1.1.8. Others
10.5.13.1.2. Bacteria
10.5.13.1.2.1. Mycoplasma Pneumoniae
10.5.13.1.2.2. Chlamydophila Pneumonia
10.5.13.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.13.2.1. Syndromic Full Multiplex Panel
10.5.13.2.2. Low Plex Panel
10.5.13.3. Market Value Forecast, by End-user, 2017–2031
10.5.13.3.1. Hospital Point-of-Care testing
10.5.13.3.2. Ref Laboratories
10.5.13.3.3. Hospitals
10.5.13.3.4. Others
10.5.14. Rest of Europe
10.5.14.1. Market Value Forecast, by Specimen Type, 2017–2031
10.5.14.1.1. Viruses
10.5.14.1.1.1. Adenovirus
10.5.14.1.1.2. Severe Acute Respiratory Syndrome
10.5.14.1.1.3. RSV
10.5.14.1.1.4. Human Metapneumovirus
10.5.14.1.1.5. Rhinovirus/Enterovirus
10.5.14.1.1.6. Parainfluenza Virus
10.5.14.1.1.7. Flu A
10.5.14.1.1.8. Others
10.5.14.1.2. Bacteria
10.5.14.1.2.1. Mycoplasma Pneumoniae
10.5.14.1.2.2. Chlamydophila Pneumonia
10.5.14.2. Market Value Forecast, by Panel Type, 2017–2031
10.5.14.2.1. Syndromic Full Multiplex Panel
10.5.14.2.2. Low Plex Panel
10.5.14.3. Market Value Forecast, by End-user, 2017–2031
10.5.14.3.1. Hospital Point-of-Care testing
10.5.14.3.2. Ref Laboratories
10.5.14.3.3. Hospitals
10.5.14.3.4. Others
10.6. Market Attractiveness Analysis
10.6.1. By Specimen Type
10.6.2. By Panel Type
10.6.3. By End-user
10.6.4. By Country/Sub-region
11. Middle East & Africa Respiratory Panel Testing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
11.2.1. Viruses
11.2.1.1. Adenovirus
11.2.1.2. Severe Acute Respiratory Syndrome
11.2.1.3. RSV
11.2.1.4. Human Metapneumovirus
11.2.1.5. Rhinovirus/Enterovirus
11.2.1.6. Parainfluenza Virus
11.2.1.7. Flu A
11.2.1.8. Others
11.2.2. Bacteria
11.2.2.1. Mycoplasma Pneumoniae
11.2.2.2. Chlamydophila Pneumonia
11.3. Market Value Forecast, by Panel Type, 2017–2031
11.3.1. Syndromic Full Multiplex Panel
11.3.2. Low Plex Panel
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospital Point-of-Care testing
11.4.2. Ref Laboratories
11.4.3. Hospitals
11.4.4. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. GCC Countries
11.5.1.1. Market Value Forecast, by Specimen Type, 2017–2031
11.5.1.1.1. Viruses
11.5.1.1.1.1. Adenovirus
11.5.1.1.1.2. Severe Acute Respiratory Syndrome
11.5.1.1.1.3. RSV
11.5.1.1.1.4. Human Metapneumovirus
11.5.1.1.1.5. Rhinovirus/Enterovirus
11.5.1.1.1.6. Parainfluenza Virus
11.5.1.1.1.7. Flu A
11.5.1.1.1.8. Others
11.5.1.1.2. Bacteria
11.5.1.1.2.1. Mycoplasma Pneumoniae
11.5.1.1.2.2. Chlamydophila Pneumonia
11.5.1.2. Market Value Forecast, by Panel Type, 2017–2031
11.5.1.2.1. Syndromic Full Multiplex Panel
11.5.1.2.2. Low Plex Panel
11.5.1.3. Market Value Forecast, by End-user, 2017–2031
11.5.1.3.1. Hospital Point-of-Care testing
11.5.1.3.2. Ref Laboratories
11.5.1.3.3. Hospitals
11.5.1.3.4. Others
11.5.2. South Africa
11.5.2.1. Market Value Forecast, by Specimen Type, 2017–2031
11.5.2.1.1. Viruses
11.5.2.1.1.1. Adenovirus
11.5.2.1.1.2. Severe Acute Respiratory Syndrome
11.5.2.1.1.3. RSV
11.5.2.1.1.4. Human Metapneumovirus
11.5.2.1.1.5. Rhinovirus/Enterovirus
11.5.2.1.1.6. Parainfluenza Virus
11.5.2.1.1.7. Flu A
11.5.2.1.1.8. Others
11.5.2.1.2. Bacteria
11.5.2.1.2.1. Mycoplasma Pneumoniae
11.5.2.1.2.2. Chlamydophila Pneumonia
11.5.2.2. Market Value Forecast, by Panel Type, 2017–2031
11.5.2.2.1. Syndromic Full Multiplex Panel
11.5.2.2.2. Low Plex Panel
11.5.2.3. Market Value Forecast, by End-user, 2017–2031
11.5.2.3.1. Hospital Point-of-Care testing
11.5.2.3.2. Ref Laboratories
11.5.2.3.3. Hospitals
11.5.2.3.4. Others
11.5.3. Rest of Middle East & Africa
11.5.3.1. Market Value Forecast, by Specimen Type, 2017–2031
11.5.3.1.1. Viruses
11.5.3.1.1.1. Adenovirus
11.5.3.1.1.2. Severe Acute Respiratory Syndrome
11.5.3.1.1.3. RSV
11.5.3.1.1.4. Human Metapneumovirus
11.5.3.1.1.5. Rhinovirus/Enterovirus
11.5.3.1.1.6. Parainfluenza Virus
11.5.3.1.1.7. Flu A
11.5.3.1.1.8. Others
11.5.3.1.2. Bacteria
11.5.3.1.2.1. Mycoplasma Pneumoniae
11.5.3.1.2.2. Chlamydophila Pneumonia
11.5.3.2. Market Value Forecast, by Panel Type, 2017–2031
11.5.3.2.1. Syndromic Full Multiplex Panel
11.5.3.2.2. Low Plex Panel
11.5.3.3. Market Value Forecast, by End-user, 2017–2031
11.5.3.3.1. Hospital Point-of-Care testing
11.5.3.3.2. Ref Laboratories
11.5.3.3.3. Hospitals
11.5.3.3.4. Others
12. Competitive Landscape
12.1. Market Player –Competition Matrix (By Tier and Size of companies)
12.2. Company Profiles (2020)
12.2.1. F. Hoffmann-La Roche Ltd.
12.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.1.2. Product Portfolio
12.2.1.3. Financial Overview
12.2.1.4. Strategic Overview
12.2.1.5. SWOT Analysis
12.2.2. bioMerieux SA
12.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.2.2. Product Portfolio
12.2.2.3. Financial Overview
12.2.2.4. Strategic Overview
12.2.2.5. SWOT Analysis
12.2.3. Medline Industries, Inc.
12.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.3.2. Product Portfolio
12.2.3.3. Strategic Overview
12.2.3.4. SWOT Analysis
12.2.4. Becton, Dickinson & Company
12.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.4.2. Product Portfolio
12.2.4.3. Financial Overview
12.2.4.4. Strategic Overview
12.2.4.5. SWOT Analysis
12.2.5. altona Diagnostics GmbH
12.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.5.2. Product Portfolio
12.2.5.3. Strategic Overview
12.2.5.4. SWOT Analysis
12.2.6. CerTest Biotec S.L.
12.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.6.2. Product Portfolio
12.2.6.3. Strategic Overview
12.2.6.4. SWOT Analysis
12.2.7. Anatolia Geneworks
12.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.7.2. Product Portfolio
12.2.7.3. Strategic Overview
12.2.7.4. SWOT Analysis
12.2.8. Seegene, Inc.
12.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.8.2. Product Portfolio
12.2.8.3. Strategic Overview
12.2.8.4. SWOT Analysis
12.2.9. DiaSorin S.p.A. (Luminex)
12.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.9.2. Product Portfolio
12.2.9.3. Financial Overview
12.2.9.4. Strategic Overview
12.2.9.5. SWOT Analysis
12.2.10. QIAGEN
12.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.10.2. Product Portfolio
12.2.10.3. Financial Overview
12.2.10.4. Strategic Overview
12.2.10.5. SWOT Analysis
12.2.11. Biocartis
12.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.11.2. Product Portfolio
12.2.11.3. Strategic Overview
12.2.11.4. SWOT Analysis
List of Tables
Table 01: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
Table 02: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031
Table 03: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031
Table 04: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031
Table 05: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 06: Europe and Middle East & Africa Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 07: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 08: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
Table 09: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031
Table 10: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031
Table 11: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031
Table 12: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 13: Germany Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
Table 14: Germany Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031
Table 15: Germany Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031
Table 16: Germany Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031
Table 17: Germany Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 18: U.K. Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
Table 19: U.K. Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031
Table 20: U.K. Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031
Table 21: U.K. Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031
Table 22: U.K. Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 23: France Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
Table 24: France Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031
Table 25: France Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031
Table 26: France Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031
Table 27: France Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 28: Italy Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
Table 29: Italy Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031
Table 30: Italy Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031
Table 31: Italy Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031
Table 32: Italy Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 33: Spain Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
Table 34: Spain Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031
Table 35: Spain Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031
Table 36: Spain Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031
Table 37: Spain Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 38: Sweden Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
Table 39: Sweden Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031
Table 40: Sweden Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031
Table 41: Sweden Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031
Table 42: Sweden Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 43: Denmark Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
Table 44: Denmark Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031
Table 45: Denmark Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031
Table 46: Denmark Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031
Table 47: Denmark Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 48: Finland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
Table 49: Finland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031
Table 50: Finland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031
Table 51: Finland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031
Table 52: Finland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 53: Austria Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
Table 54: Austria Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031
Table 55: Austria Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031
Table 56: Austria Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031
Table 57: Austria Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 58: Switzerland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
Table 59: Switzerland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031
Table 60: Switzerland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031
Table 61: Switzerland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031
Table 62: Switzerland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 63: Benelux Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
Table 64: Benelux Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031
Table 65: Benelux Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031
Table 66: Benelux Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031
Table 67: Benelux Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 68: Norway Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
Table 69: Norway Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031
Table 70: Norway Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031
Table 71: Norway Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Panel Specimen Type, 2017–2031
Table 72: Norway Respiratory Panel Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 73: Poland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Specimen Type, 2017–2031
Table 74: Poland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Viruses, 2017–2031
Table 75: Poland Respiratory Panel Testing Market Value (US$ Mn) Forecast, by Bacteria, 2017–2031
List of Figures
Figure 01: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share, by Panel Specimen Type, 2020
Figure 03: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share, by Specimen Type, 2020
Figure 04: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share, by End-user, 2020
Figure 05: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share, by Region, 2020
Figure 06: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031
Figure 07: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031
Figure 08: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Viruses, 2017–2031
Figure 09: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Bacteria, 2017–2031
Figure 10: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031
Figure 11: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031
Figure 12: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Syndromic Full Multiplex Panel, 2017–2031
Figure 13: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Low Plex Panel, 2017–2031
Figure 14: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 15: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 16: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Hospital Point-of-Care Testing, 2017–2031
Figure 17: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Ref Laboratories, 2017–2031
Figure 18: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Hospitals, 2017–2031
Figure 19: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Value (US$ Mn), by Others, 2017–2031
Figure 20: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Analysis, 2020 and 2031
Figure 21: EUROPE AND MIDDLE EAST & AFRICA Respiratory Panel Testing Market Attractiveness Analysis, by Region, 2021–2031
Figure 22: Europe Respiratory Panel Testing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 23: Europe Respiratory Panel Testing Market Value Share, by Country/Sub-region, 2020–2031
Figure 24: Europe Respiratory Panel Testing Market Attractiveness, by Country/Sub-region, 2021–2031
Figure 25: Europe Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031
Figure 26: Europe Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031
Figure 27: Europe Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031
Figure 28: Europe Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031
Figure 29: Europe Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 30: Europe Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 31: Germany Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031
Figure 32: Germany Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031
Figure 33: Germany Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031
Figure 34: Germany Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031
Figure 35: Germany Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 36: Germany Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 37: U.K. Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031
Figure 38: U.K. Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031
Figure 39: U.K. Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031
Figure 40: U.K. Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031
Figure 41: U.K. Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 42: U.K. Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 43: France Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031
Figure 44: France Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031
Figure 45: France Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031
Figure 46: France Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031
Figure 47: France Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 48: France Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 49: Italy Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031
Figure 50: Italy Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031
Figure 51: Italy Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031
Figure 52: Italy Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031
Figure 53: Italy Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 54: Italy Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 55: Spain Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031
Figure 56: Spain Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031
Figure 57: Spain Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031
Figure 58: Spain Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031
Figure 59: Spain Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 60: Spain Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 61: Sweden Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031
Figure 62: Sweden Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031
Figure 63: Sweden Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031
Figure 64: Sweden Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031
Figure 65: Sweden Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 66: Sweden Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 67: Denmark Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031
Figure 68: Denmark Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031
Figure 69: Denmark Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031
Figure 70: Denmark Respiratory Panel Testing Market Attractiveness Analysis, by Panel Specimen Type, 2021–2031
Figure 71: Denmark Respiratory Panel Testing Market Value Share Analysis, by End-user, 2020 and 2031
Figure 72: Denmark Respiratory Panel Testing Market Attractiveness Analysis, by End-user, 2021–2031
Figure 73: Finland Respiratory Panel Testing Market Value Share Analysis, by Specimen Type, 2020 and 2031
Figure 74: Finland Respiratory Panel Testing Market Attractiveness Analysis, by Specimen Type, 2021–2031
Figure 75: Finland Respiratory Panel Testing Market Value Share Analysis, by Panel Specimen Type, 2020 and 2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Respiratory Panel Testing Market
